Home › Cases › The Headache Without Visual Symptoms
Giant Cell Arteritis
The Headache Without Visual Symptoms
6 questions
Question 1 · A Different Dose
Correct answer: Prednisolone 40–60mg orally daily
Why
No visual symptoms: prednisolone 40 to 60mg orally daily.
- IV methylprednisolone 500mg to 1g for 3 days is reserved for visual involvement, where the aim is to save the fellow eye
- Never wait for the biopsy — the diagnosis is treated on clinical suspicion, and steroids do not obscure the histology for 2 to 6 weeks
- Distinguishing the two doses matters in both directions: under-treating visual GCA costs an eye; over-treating non-visual GCA gives an unnecessary steroid load
- Rheumatology fast-track pathway for everyone
Key point
Oral 40–60mg without visual symptoms; IV methylpred with them. The eye is what changes the dose.
Question 2 · Normal Markers
Correct answer: No — ESR and CRP are normal in around 5% of cases
Why
ESR and CRP are raised in most cases but normal in around 5%.
- So a normal result lowers the probability without excluding the diagnosis, and in a patient with jaw claudication and a new headache over 50 the clinical picture carries more weight
- This mirrors other pathways: a normal serum urate does not exclude gout, a normal CSF does not exclude HSV, a normal chest X-ray does not exclude PE
- Temporal artery ultrasound and biopsy are how the diagnosis is pursued
- Treating a patient with a normal ESR is entirely appropriate if the clinical suspicion is high
Key point
Five per cent have normal markers. Jaw claudication over 50 outweighs a normal ESR.
Question 3 · The Fellow Eye
Correct answer: Escalate to IV methylprednisolone and arrange same-day ophthalmology — fellow-eye or new visual symptoms on treatment is an escalation trigger
Why
Fellow-eye symptoms developing on treatment is an explicit escalation trigger, and any visual symptom means IV steroids now plus same-day ophthalmology.
- The appearance of visual symptoms changes his category entirely — he is now in the group at risk of irreversible blindness
- Doubling the oral dose is not the same as IV methylprednisolone 500mg to 1g, and the difference matters when the outcome is permanent
- Clinic review is far too slow
- Watch the fellow eye is written into the pathway because bilateral involvement is a real and devastating outcome
Key point
New visual symptoms on treatment changes the drug, not the dose. IV methylpred, same-day ophthalmology.
Question 4 · Beyond the Temporal Artery
Correct answer: Large-vessel involvement — aortic or subclavian — needing vascular imaging
Why
Limb claudication or suspected aortic involvement is an escalation trigger for vascular imaging.
- GCA is a large-vessel vasculitis, and the temporal artery is simply the most accessible one. The aorta, subclavian and axillary arteries can all be involved
- Consequences include aortic aneurysm and dissection, sometimes years later, which is why long-term follow-up matters
- Unequal blood pressures between arms is a classic sign of subclavian involvement
- Imaging is typically CT or MR angiography, or PET-CT
- Steroids do not cause claudication
Key point
GCA is a large-vessel vasculitis. Unequal arm pressures or limb claudication means image the aorta.
Question 5 · The Overlap
Correct answer: Polymyalgia rheumatica — overlapping with GCA in 40 to 60% of cases
Why
PMR overlaps with GCA in 40 to 60% of cases.
- Proximal girdle pain and morning stiffness in a patient over 50 with raised inflammatory markers is the classic PMR picture, and it frequently coexists with GCA
- It matters because PMR alone is treated with much lower steroid doses (typically 15mg) — so a patient on the PMR pathway who develops headache or visual symptoms must be recognised as having GCA and escalated immediately
- Steroid myopathy causes weakness rather than pain and stiffness, and develops later
- The overlap is worth asking about directly in every GCA patient
Key point
Ask about girdle stiffness in every GCA patient — and about headache in every PMR patient.
Question 6 · Relapse
Correct answer: Rheumatology — relapse during the taper is an escalation trigger, and tocilizumab or methotrexate may be added
Why
Relapse during the taper is an escalation trigger for rheumatology, and tocilizumab or methotrexate is used for relapsing disease.
- Steroid-sparing agents matter enormously here: a patient relapsing at nine months faces a further prolonged course, and the cumulative steroid burden is what causes the fractures, diabetes and cataracts
- The dose is increased and the taper restarted more slowly, not stopped
- Continuing the taper through a relapse risks visual loss — the whole reason for treating GCA at all
- Check the bone protection and glucose monitoring are still in place, since the course is now considerably longer
Key point
Relapse means rheumatology and a steroid-sparing agent — not pushing on through the taper.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.